April 11, 2018—Beckman Coulter Diagnostics announced the launch of its Access Sensitive Estradiol assay in the U.S. and in a majority of markets worldwide. The test is commonly ordered for detecting estradiol levels in women, children, and men.
The assay aims to help laboratories deliver more accurate results for patients seeking answers to reproductive health questions. It has a broad measuring range, surpassing clinical decision limits for in vitro fertilization hyper responders. This may allow laboratories to report accurate patient results while avoiding costly dilutions of samples from patients undergoing IVF. The Access Sensitive Estradiol is “the only assay in the market with published pediatric reference ranges,” according to a press release from the company.
“The new Access Sensitive Estradiol assay offers improved measurement of low levels of estradiol, such as those typically found in men, pediatric populations, and postmenopausal women,” Michael Samoszuk, MD, chief medical officer of Beckman Coulter Diagnostics, said in the release. “There is emerging evidence that estradiol levels play an important role in maintaining men’s reproductive health. Hence, this new assay will enable accurate testing for estradiol in all patient populations.”
The Access Sensitive Estradiol adds to the company’s menu of reproductive endocrinology and prenatal screening assays and is for use on the company’s immunoassay systems, including the Access 2, DxI 600, and DxI 800.